{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Complement+Activity", "query": { "condition": "Complement Activity" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 8, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T18:11:34.464Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02946463", "title": "ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Nocturnal Hemoglobinuria (PNH)" ], "interventions": [ { "name": "Ravulizumab", "type": "BIOLOGICAL" }, { "name": "Eculizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 272, "start_date": "2016-12-12", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2024-05-14", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 3, "location_summary": "Los Angeles, California • Whittier, California • Fort Worth, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02946463" }, { "nct_id": "NCT01919346", "title": "Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Delayed Graft Function", "Kidney Transplantation", "Complement Activity" ], "interventions": [ { "name": "Eculizumab", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heeger, Peter, M.D.", "sponsor_class": "INDIV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2013-08", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-02-27", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 5, "location_summary": "New Haven, Connecticut • New York, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01919346" }, { "nct_id": "NCT04432584", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Paroxysmal Nocturnal Hemoglobinuria" ], "interventions": [ { "name": "Crovalimab", "type": "DRUG" }, { "name": "Eculizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 190, "start_date": "2020-09-30", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 2, "location_summary": "Charlotte, North Carolina • Columbus, Ohio", "locations": [ { "city": "Charlotte", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04432584" }, { "nct_id": "NCT02994927", "title": "A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "ANCA-Associated Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Azathioprine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 331, "start_date": "2017-03-15", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 41, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02994927" }, { "nct_id": "NCT05695248", "title": "A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Navenibart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astria Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-02-21", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05695248" }, { "nct_id": "NCT00000421", "title": "Serologically Active, Clinically Stable Systemic Lupus Erythematosus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "13 Years to 65 Years · Female only" }, "enrollment_count": 154, "start_date": "1997-09", "completion_date": "2003-08", "has_results": false, "last_update_posted_date": "2016-03-04", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 3, "location_summary": "New Hyde Park, New York • New York, New York • The Bronx, New York", "locations": [ { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000421" }, { "nct_id": "NCT05988034", "title": "A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Electrocardiography" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo for avacopan", "type": "DRUG" }, { "name": "Placebo for moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 58, "start_date": "2019-11-08", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05988034" }, { "nct_id": "NCT04723602", "title": "Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ebola Virus Disease", "Marburg Virus Disease" ], "interventions": [ { "name": "cAd3-Marburg", "type": "BIOLOGICAL" }, { "name": "cAd3-EBO-S", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Albert B. Sabin Vaccine Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 32, "start_date": "2021-01-06", "completion_date": "2021-12-14", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-07-23T18:11:34.464Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04723602" } ] }